UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022
Late-breaking 52-week data on investigational bimekizumab in the treatment of adults with active psoriatic arthritis and active axial spondyloarthritis to be presentedNew data on CIMZIA® (certolizumab pegol) and bimekizumab underscore UCB’s commitment to innovative research in rheumatology Brussels (B...